Document is current
Any future updates will be listed below
-
Authors
Zhang, Yajun
Zhang, Zhiwei
Ding, Yongmei
Fang, Yuan
Wang, Pei
Chu, Wenqi
Jin, Zhenlin
Yang, Xintao
Wang, Jiangtao
Lou, Jinxing
Qian, Qijun https://orcid.org/0000-0002-3285-5009
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03182816 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients
https://doi.org/10.1007/s00432-021-03613-7
-
Funding
Funding for this research was provided by:
the National Key Research and Development Program (2017YFC0909800)
the National Key Research and Development Program of China (2019YFC1316202)
- License Information
-
More Information
Article History
Received: 26 November 2020
Accepted: 22 March 2021
First Online: 25 May 2021
Declarations
:
: The authors declared that there are no conflicts of interest in this work.
: This study was approved and supervised by the Medical Ethics Committee of Ningbo No. 5 Hospital with approval number of H2017-03-P01. The study was performed in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Consent for publication has been obtained by the participants.
